Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | HTR2C | P28335 | 4/20 | 0.59 |
| ▸ | HTR2B | P41595 | 4/20 | 0.59 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | CCR4 | P51679 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815654 | 0.93 | SIGMAR1 (0.51) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7507555 | 0.93 | SIGMAR1 (0.51) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL31334285 | 0.89 | DRD2 (0.47) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL24881010 | 0.88 | KCNH2 (0.48) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL24881009 | 0.88 | CHRM2 (0.51) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL19122610 | 0.86 | USP30 (0.54) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL24872889 | 0.86 | MBTD1 (0.48) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL24872890 | 0.86 | OPRM1 (0.46) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL30112474 | 0.86 | OPRM1 (0.46) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL30112429 | 0.86 | MBTD1 (0.48) | SIGMAR1HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1904479-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| EP-1103560-B1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-12-27 | — | — | EP | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0842174-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PF MEDICAMENT (FR) | 2001-10-04 | — | — | EP | disclosed |
| EP-1103560-A1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-6011032-A | Heterocyclic compounds for treating myocardial ischemia | PIERRE FABRE MEDICAMENT (FR) | 2000-01-04 | — | — | US | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| EP-0842174-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005134-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1997-02-13 | — | — | WO | disclosed |
| US-5214055-A | Analgesics, psychological disorders, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-05-25 | — | — | US | disclosed |
| US-5189045-A | Antiserotonine agent | ADIR ET COMPAGNIE (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | SIGMAR1 238/4885HTR2A 145/4885HTR2C 57/4885 |
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | SIGMAR1 4101/4885HTR2A 3453/4885HTR2C 3934/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | SIGMAR1 369/4885HTR2A 475/4885HTR2C 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.